Archives: “Type 1 Diabetes”

Andrew Wells, PhD

Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania Dr. Andrew Wells is Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine, […]

Creating Insulin Producing Beta Cells That Resist Autoimmune Destruction

Engineering TET2-deficient beta cells that resist autoimmune attack to create replacement cell therapies for type 1 diabetes.

Using Genetically Engineered Models to Study Pre-Autoimmune States

Using the RIP-NINJA mouse model to study how PD-1 regulation in the pancreas prevents autoimmune induction and checkpoint therapy-induced diabetes.

Development of Rationally Designed PD-1 Agonist Biologics for the Treatment of Autoimmune Diseases

Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.

Colton Center for RNA Exploration in Autoimmune Therapeutics (CREATE)

Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab

Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup

Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes

Diabetes mellitus—progress and opportunities in the evolving epidemic

Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes